Scil Technology Appoints New VP of Corporate Development

MARTINSRIED, Germany, July 3, 2006 – Scil Technology, a biopharmaceutical company focused on the development of dental and orthopaedic tissue regeneration products, today announced the appointment of Volker Lang, Ph.D., as its new Vice President of Corporate Development.

Dr. Lang joins Scil Technology from Pieris Proteolab AG, where he was Vice President of Business Development. At Pieris, in addition to securing strategic deals with leading Pharma and in vivo diagnostics companies, he negotiated a number of in-licensing agreements for technologies, targets, and other resources that add value to the company’s technology platform. In  his 15 years experience in the biotechnology sector, spanning basic research, industrial R&D, Business Development & Licensing, and commercial operations & management, Dr. Lang contributed significantly in the scientific development and commercialization of biological agents for industrial and healthcare applications.

“Beside his high analytical skills and creativity, Dr. Lang has broad scientific knowledge and extensive experience in the sector of Business Development,” said Dr. Weishui Weiser, Managing Director of Scil Technology GmbH. “I am confident he will accelerate the commercialisation of Scil’s projects leading to long lasting, viable success for Scil Technology”.

“I am excited and honoured to join Scil Technology in this important development-phase of the company,“ said Dr. Volker Lang, the new VP Corporate Development of Scil Technology. “The company consists of a highly motivated and skilled team, has established a structure with full pharmaceutical development capacity and achieved excellent data for a number of its projects, not only in animals but also in man. This is a very promising ground for successful Corporate Development.”

Dr. Lang combines a background as scientist and project manager with extensive experience in the commercialisation of biotechnology products. He has also gained considerable CMC/Production experience in his previous positions. Dr. Lang received his Ph.D. from the Technical University of Brunswick. After that he worked as an industry scientist and project manager with UCB-Celltech and Fresenius-Kabi, respectively.  He joined Cosmix GmbH, Brunswick as Head of Business Development, and later Chief Operating Officer.

About Scil Technology GmbH

Scil Technology is a private biopharmaceutical development company focused on dental and orthopaedic tissue regeneration with a particular emphasis on bone and cartilage repair. The Company’s therapeutic product candidates are based on recombinant, highly specific human growth factors. These are combined with biodegradable biomaterials to generate local application forms. Scil Technology’s pipeline for dentistry includes products that are targeted at periodontal disease, dental implantology and maxillofacial surgery. Orthopaedic products are developed for spinal fusion, bone trauma, joint cartilage defects and osteoarthritis. Scil Technology has emerged from the Scil Group and is located in the biotechnology cluster in Martinsried, Germany.

For more information please visit: http://www.sciltechnology.com

Contacts

Media relations:

Douglas Pretsell, Ph.D., Account Director
Northbank Communications
t : +49 (0)89 57 00 18 06
e:  d.pretsell@northbankcommunications.com

At Scil Technology:

Dr. Weishui Weiser, Managing Director
Scil Technology GmbH
t: +49 (0)89 85651824
e: weishui.weiser@sciltechnology.com